Fast Track

You have full text access to this OnlineOpen article

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis

  1. Nicholas F.S. Watson1,2,
  2. Judith M. Ramage1,
  3. Zahra Madjd1,
  4. Ian Spendlove1,
  5. Ian O. Ellis3,
  6. John H. Scholefield2,
  7. Lindy G. Durrant1,†,*

Article first published online: 7 JUL 2005

DOI: 10.1002/ijc.21303

Issue

International Journal of Cancer

International Journal of Cancer

Volume 118, Issue 1, pages 6–10, 1 January 2006

Additional Information

How to Cite

Watson, N. F.S., Ramage, J. M., Madjd, Z., Spendlove, I., Ellis, I. O., Scholefield, J. H. and Durrant, L. G. (2006), Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer, 118: 6–10. doi: 10.1002/ijc.21303

Author Information

  1. 1

    Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, United Kingdom

  2. 2

    Section of Gastrointestinal Surgery, University of Nottingham, Queens' Medical Centre, Nottingham, United Kingdom

  3. 3

    Department of Histopathology, Nottingham City Hospital, Nottingham, United Kingdom

  1. †

    Fax: +44-115-962-7923.

*Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, NG5 1PB, UK

Publication History

  1. Issue published online: 26 OCT 2005
  2. Article first published online: 7 JUL 2005
  3. Manuscript Accepted: 6 MAY 2005
  4. Manuscript Received: 4 MAR 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (387K)

References

  • 1
    Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004; 22: 329–60.
  • 2
    Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117–58.
  • 3
    Parham P. Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G. Am J Reprod Immunol 1995; 34: 10–9.
  • 4
    Ljunggren HG, Karre K. In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237–44.
  • 5
    Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, van De Velde CJ, Fleuren GJ, Kuppen PJ. Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 2002; 82: 1725–33.
  • 6
    Eyal A, Levin I, Segal S, Levi I, Klein B, Kuperman O. Variation of HLA-ABC surface antigen expression on adenocarcinoma of the colon in correlation with the degree of differentiation. Nat Immun Cell Growth Regul 1990; 9: 222–7.
  • 7
    Stein B, Momburg F, Schwarz V, Schlag P, Moldenhauer G, Moller P. Reduction or loss of HLA-A,B,C antigens in colorectal carcinoma appears not to influence survival. Br J Cancer 1988; 57: 364–8.
  • 8
    Menon A, Tollenaar R, van de Velde CJ, Putter H, Janssen-Van Rhijn CM, Keijzer R, Fleuren GJ, Kuppen PJ. p53 and HLA class-I expression are not down regulated in colorectal cancer liver metastases. Clin Exp Metastasis 2004; 21: 79–85.
  • 9
    Kallioniemi O, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10: 657–62.
  • 10
    Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844–7.
  • 11
    Stam N, Spits H, Ploegh H. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137: 2299–306.
  • 12
    Stam N, Vroom T, Peters P, Pastoors EB, Ploegh H. HLA-A and HLA-B specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990; 2: 113–25.
  • 13
    Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003; 171: 1918–26.
  • 14
    Cabrera C, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: Beta-2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003; 61: 211–9.
    Direct Link:
  • 15
    Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales 1950–1999. London: The Stationary Office, 2001.
  • 16
    Sugita M, Brenner M. An unstable beta2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med 1994; 180: 2163–71.
  • 17
    Hudson A, Ploegh H. The cell biology of antigen presentation. Exp Cell Res 2002; 272: 1–7.
  • 18
    Kang J, Yoon S, Kim N, Heo D. The expression of MHC class I, TAP1/TAP2, and LMP2/7 genes in human cancer cell lines. Int J Oncol 2000; 16: 1159–63.
  • 19
    Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89–95.
  • 20
    Sandel MH, Speetjens FM, Menon AG, Albertsson PA, Basse PH, Hokland M, Nagelkerke JF, Tollenaar RA, van de Velde CJ, Kuppen PJ. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol 2005; 42; 541–6.
View Full Article (HTML) Get PDF (387K)